<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Mol Med</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol. Med</journal-id>
<journal-title-group>
<journal-title>Molecular Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1076-1551</issn>
<issn pub-type="epub">1528-3658</issn>
<publisher>
<publisher-name>Feinstein Institute for Medical Research</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27579475</article-id>
<article-id pub-id-type="pmc">5082297</article-id>
<article-id pub-id-type="doi">10.2119/molmed.2015.00170</article-id>
<article-id pub-id-type="publisher-id">2015.00170</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Cadherin 13: Human <italic>cis</italic>-Regulation and Selectively Altered Addiction Phenotypes and Cerebral Cortical Dopamine in Knockout Mice</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Drgonova</surname>
<given-names>Jana</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Walther</surname>
<given-names>Donna</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hartstein</surname>
<given-names>G Luke</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bukhari</surname>
<given-names>Mohammad O</given-names>
</name>
<xref ref-type="aff" rid="aff1">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baumann</surname>
<given-names>Michael H</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Katz</surname>
<given-names>Jonathan</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hall</surname>
<given-names>F Scott</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arnold</surname>
<given-names>Elizabeth R</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Flax</surname>
<given-names>Shaun</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Riley</surname>
<given-names>Anthony</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rivero</surname>
<given-names>Olga</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lesch</surname>
<given-names>Klaus-Peter</given-names>
</name>
<xref ref-type="aff" rid="aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Troncoso</surname>
<given-names>Juan</given-names>
</name>
<xref ref-type="aff" rid="aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ranscht</surname>
<given-names>Barbara</given-names>
</name>
<xref ref-type="aff" rid="aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Uhl</surname>
<given-names>George R</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff7">7</xref>
</contrib>
<aff id="aff1"><label>1</label>Molecular Neurobiology, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland, United States of America;</aff>
<aff id="aff2"><label>2</label>Medicinal Chemistry, National Institute on Drug Abuse, Intramural Research Program, Baltimore, Maryland, United States of America;</aff>
<aff id="aff3"><label>3</label>Department of Psychology, American University, Washington, DC, United States of America;</aff>
<aff id="aff4"><label>4</label>Translational Neurobiology, Department of Psychiatry, University of Wörzburg, Wörzburg, Germany;</aff>
<aff id="aff5"><label>5</label>Division of Neuropathology, Johns Hopkins School of Medicine, Baltimore Maryland, United States of America;</aff>
<aff id="aff6"><label>6</label>Sanford-Burnham Medical Research Institute, La Jolla, California, United States of America;</aff>
<aff id="aff7"><label>7</label>Research, New Mexico VA Healthcare System, Albuquerque, New Mexico, United States of America</aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Address correspondence to George Uhl, Research, Building 66, Room 127, New Mexico VA Healthcare System, 1501 San Pedro SE, Albuquerque, New Mexico 87111, USA. Phone: +1-505-265-1711, x4712; E-mail: <email>George.Uhl@va.gov</email>.</corresp>
<fn fn-type="COI-statement">
<p>
<bold>DISCLOSURE</bold>
</p>
<p>This work was supported by the National Institutes of Health (NIH)–Intramural Research Program, NIDA, DHHS and the Biomedical Research Institute of New Mexico (G Uhl), NIH grant HL102680 (B Ranscht), the European Community (EC: AGGRESSOTYPE FP7/No. 602805 (OR and KPL), the DFG (SFB TRR 58/A5 OR and KPL) and the Fritz Thyssen Foundation (Az.10.13.1185 OR and KPL).</p>
</fn>
</author-notes>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>18</day>
<month>8</month>
<year>2016</year>
</pub-date>
<volume>22</volume>
<fpage>537</fpage>
<lpage>547</lpage>
<history>
<date date-type="received">
<day>15</day>
<month>7</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>7</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright: © 2016 The Feinstein Institute for Medical Research</copyright-statement>
<copyright-year>2016</copyright-year>
</permissions>
<self-uri xlink:href="mol-22-15_170_Drgonova.pdf" xlink:title="pdf" xlink:type="simple"></self-uri>
<abstract>
<p>The cadherin 13 (<italic>CDH13</italic>) gene encodes a cell adhesion molecule likely to influence development and connections of brain circuits that modulate addiction, locomotion and cognition, including those that involve midbrain dopamine neurons. Human <italic>CDH13</italic> mRNA expression differs by more than 80% in postmortem cerebral cortical samples from individuals with different <italic>CDH13</italic> genotypes, supporting examination of mice with altered CDH13 expression as models for common human variation at this locus. Constitutive <italic>CDH13</italic> knockout mice display evidence for changed cocaine reward: shifted dose response relationship in tests of cocaine-conditioned place preference using doses that do not alter cocaine-conditioned taste aversion. Reduced adult <italic>CDH13</italic> expression in conditional knockouts also alters cocaine reward in ways that correlate with individual differences in cortical <italic>CDH13</italic> mRNA levels. In control and comparison behavioral assessments, knockout mice display modestly quicker acquisition of rotarod and water maze tasks, with a trend toward faster acquisition of 5-choice serial reaction time tasks that otherwise displayed no genotype-related differences. They display significant differences in locomotion in some settings, with larger effects in males. In assessments of brain changes that might contribute to these behavioral differences, there are selective alterations of dopamine levels, dopamine/metabolite ratios, dopaminergic fiber densities and mRNA encoding the activity dependent transcription factor <italic>npas4</italic> in cerebral cortex of knockout mice. These novel data and previously reported human associations of <italic>CDH13</italic> variants with addiction, individual differences in responses to stimulant administration and attention deficit hyperactivity disorder (ADHD) phenotypes suggest that levels of <italic>CDH13</italic> expression, through mechanisms likely to include effects on mesocortical dopamine, influence stimulant reward and may contribute modestly to cognitive and locomotor phenotypes relevant to ADHD.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>